The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

The pathway leading to the telltale sign of ALS, protein aggregation in the cytoplasm of motor neurons, has been revealed. Researchers from the University of California – San Diego (CA, USA) have ...

Neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS (amyotrophic lateral sclerosis) are debilitating conditions that affect millions of people worldwide every year. These pathologies are ...

Leuven, 14 June 2024 - Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are two devastating neurodegenerative diseases. Scientists have long suspected a protein called FUS might ...

Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~50% and ~55% respectively, in M337V ...

The fluorescence microscopy images show the nuclei of cultured human cells. On the left, the protein TDP‑43 (green) is seen distributed within the cell nucleus along with nuclear bodies (red), which ...

Accumulation of a protein called TDP-43 is a key feature of ALS and frontotemporal dementia. In a newly published study, researchers report 'seeding' this accumulation through fragments of the culprit ...

Protein misfolding and mislocalization are common themes in neurodegenerative disorders, including motor neuron disease, and amyotrophic lateral sclerosis (ALS). Maintaining proteostasis is a ...

A new study from scientists at VIB-KU Leuven Center for Brain & Disease and elsewhere reveals the role of an RNA binding protein called Fused in Sarcoma (FUS) in the development of frontotemporal ...

Protein-based therapeutics have transformed treatments for numerous diseases, yet their production remains highly complex and cost-intensive [1][2],[3][4]. Downstream processing (DSP), including ...